News

Boston, February 14, 2017

The Institute of Medicinal Plant Development has licensed Scilligence’s TouchMol4Office

The Institute of Medicinal Plant Development (IMPLAD) has licensed Scilligence’s TouchMol4Office, a cheminformatics and bioinformatics plug-in for Microsoft Office. This informatics tool will significantly enhance researchers’ ability to analyze and visualize chemical compositions of natural products in medicinal herbs.

About Scilligence
Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.

About The Institute of Medicinal Plant Development
The Institute of Medicinal Plant Development (IMPLAD), and Beijing Medicinal Plant Garden, affiliated with the Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), was established in August 1983. The headquarters are located in Zhongguancun Scientific and Technical Zone, Beijing, with six branches respectively distributed in Yunan, Hainan, Guangxi, Xinjiang, Chongqing, and Guizhou. As the only one national research institution of public service specializing in protection, development, and utilization of medicinal plant resources, and also one of the well-known institutions focusing on medicinal plant research worldwide, IMPLAD is playing a leading role in research on Chinese medicinal herbs, and has been working as WHO Collaborating Center for Traditional Medicine.


Boston, February 7, 2017

The Pistoia Alliance and Scilligence Announce HELM Web Editor

The Pistoia Alliance and Scilligence Corporation are pleased to announce the release of the HELM (Hierarchical Editing Language for Macromolecules) Web Editor, which brings HELM’s industry standard biomolecular representation to the browser, greatly enhancing the deployability of the technology for its adopters.

As the therapeutic utilization of complex and unique biomolecules has become commonplace in drug discovery R&D, scientists have struggled to represent these entities in their information systems, forcing them to use various “pick and mix” approaches that include multiple nomenclatures and textual descriptions. HELM, the open biomolecular representation standard, has solved this problem by providing a means to represent various types of complex macromolecules (e.g. nucleotides, proteins, antibodies and antibody-drug conjugates) including those that contain non-natural elements such as chemically modified amino acids.

The Pistoia Alliance formalized the HELM notation, originally created by Pfizer scientists as an open standard in early 2013, and publicly released the related software toolkit and editor to the Open Source community. Since its release, HELM has benefited from a growing ecosystem of global adopters and contributors including organizations such as Bristol Myers Squibb, Pfizer, Novartis, Roche, GSK, Ionis, Merck and Co, Scilligence, NextMove Software, ACD/Labs, Arxspan, BioChemfusion, Dassault Systèmes BIOVIA, ChemAxon, Perkin-Elmer, quattro research, EMBL-EBI, NCBI (PubChem), and RDKit.

While the original HELM Applet editor, supporting HELM Notation 1.0 and developed using Java, made it easier for scientists to draw and view macromolecules, technology evolved, leaving the applet unsupported by many browsers. The new HELM Web Editor is completely built on JavaScript, which removes dependencies and increases the compatibilities with modern browsers.

2017 will see further updates to the web editor to add monomer and ruleset management, support for the HELM 2.0 ambiguity features and antibody editing.

As major contributors to this project, Novartis AG and Ionis Pharmaceuticals are adopting the new HELM Web Editor.

Dr. Eric Swayze, Vice President of Chemistry and Neuroscience Drug Discovery at Ionis Pharmaceuticals adds: “The new HELM Web Editor makes it easier for our scientists to adopt the HELM technologies, which helps them to more efficiently represent and register complex chemically modified biomolecules, which facilitates exchange of information within the team.”

Dr. Jinbo Lee, CSO of Scilligence adds: “We appreciate the opportunity working on the project. The new HELM Web Editor’s zero-footprint and enhanced usability will help the scientific community including life-science, academic, and technology organizations adopt the HELM standard.”

About Pistoia Alliance
The Pistoia Alliance is a global, not-for-profit members’ organization made up of life science companies, technology and service providers, publishers, and academic groups working to lower barriers to innovation in life science and healthcare R&D. It was conceived in 2007 and incorporated in 2009 by representatives of AstraZeneca, GSK, Novartis and Pfizer who met at a conference in Pistoia, Italy. Its projects transform R&D through pre-competitive collaboration. It overcomes common R&D obstacles by identifying the root causes, developing standards and best practices, sharing pre-competitive data and knowledge, and implementing technology pilots. There are currently over 80 member companies; members collaborate on projects that generate significant value for the worldwide life sciences R&D community, using the Pistoia Alliance’s proven framework for open innovation.
www.pistoiaalliance.org

About Scilligence
Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.
www.scilligence.com

Contact
Krystyana Roman, Marketing Specialist, Scilligence.
[email protected]
+1 (617) 520-4588

Claire Bellamy, Project Manager, Pistoia Alliance
[email protected]
+44 7823 470513

Read on Pistoia Alliance’s site


January 12, 2016

Shanghai Hengrui Pharmaceutical Co., Ltd. has licensed Scilligence ELN

Shanghai Hengrui Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Medicine Co., Ltd, has licensed Scilligence ELN (Electronic Laboratory Notebook) as a company-wide platform for their drug discovery and development effort. This State-of-the-art ELN platform will empower more efficient collaborations and knowledge management within the company and with external collaborators including CROs.


About Scilligence

Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.


About Shanghai Hengrui Pharmaceutical Co., Ltd
Shanghai Hengrui Pharmaceutical Co. Ltd. is the research and development Center of Jiangsu Hengrui Medicine Co., Ltd., which is a fully integrated pharmaceutical company in China, with annual net sales of over U.S. $1.4 billion. Hengrui is recognized as the top innovative Chinese drug company, with about 20 new molecular entities entering clinical trials and dozens more under pre-clinical development. Hengrui’s products and R&D span over multiple therapeutic areas, such as oncology and hematology, anesthesiology and pain management, cardiovascular and metabolic diseases, contrast media, and anti-inflammation. Please visit http://www.shhrp.com and http://www.hrs.com.cn for further information.


December 22, 2016

Shanghai Syn-The-All Pharmaceutical Co. Ltd. (STA) has licensed Scilligence ELN

Shanghai Syn-The-All Pharmaceutical Co. Ltd. (STA), a subsidiary of WuXi AppTec, has licensed Scilligence ELN (Electronic Laboratory Notebook) as a company-wide platform. This is yet another major collaboration since WuXi AppTec’s Chemistry Service Unit first implemented Scilligence ELN more than 3 years ago.


About Scilligence

Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.


About WuXi AppTec

WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi platform is enabling more than 2,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi’s dream that “every drug can be made and every disease can be treated.” Please visit www.wuxiapptec.com for more information about WuXi AppTec.


About STA

Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA), a WuXi AppTec company, is a leading small molecule process development and manufacturing capability and technology platform company serving the life science industry, with operations in China and the United States. As a premier Contract Development and Manufacturing Organization (CDMO), STA offers our worldwide partners efficient, flexible and high-quality solutions for small molecule Active Pharmaceutical Ingredients (APIs) and advanced intermediates from preclinical to commercial. For more information, please visit www.STApharma.com

 


August 11, 2016

Scilligence Launches New Brand Identity

If you are in the pharma and biotech industry, you have probably heard of the up and coming startup that provides scientists and researchers with integrated informatics platforms that facilitate collaboration and address knowledge, project, workflow and material management. Scilligence has seen some impressive growth since its start in 2010 with wide adoption of its informatics solutions by pharma, biotech, and chemical companies; government agencies; research institutes; hospitals; and universities. After experiencing ample expansion, Scilligence decided it was time to revamp their brand and logo.

The Scilligence name, is a combination of the words “Science” and “Intelligence”. The new logo needed to capture these two aspects so you could see them as separate entities but also working together. The new logo (right) is much more modern and less mechanical than the old one (left). The color palette was chosen to display Scilligence’s creative, collaborative side (yellow) and its sophisticated, intellectual side (purple). The lightbulb image contains a DNA helix and a small molecule to signify Scilligence’s biggest accomplishment: the first to develop informatics platform that bridged small molecules and biologics. The logo and new brand showcase what differentiates Scilligence from its competitors and the bright future ahead for the company.

To learn more about Scilligence please visit the newly designed and user-friendly site: www.scilligence.com. Scilligence is currently offering TouchMol4Office (Microsoft Office add-in that enables cheminformatics and bioinformatics) free for academia!